Physiological Changes in Adults With Metabolic Syndrome Exposed to Ultrafine Air Particles (XCON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01475968
Recruitment Status : Completed
First Posted : November 22, 2011
Last Update Posted : November 7, 2013
Environmental Protection Agency (EPA)
Information provided by (Responsible Party):
David Diaz-Sanchez, Environmental Protection Agency (EPA)

Brief Summary:
The purpose of this study is to examine the acute health effects of concentrated ambient ultrafine (UF) particulate matter (PM) exposure in patients with metabolic syndrome. Without lifestyle changes or medical intervention these patients are at considerable risk for developing diabetes and cardiovascular disease. Subjects (25-70) were exposed to both UF PM and filtered air for 2hr (at least 2 week interval), physiologic endpoints were measure pre-, post-, and 20hr post-exposure. Our hypothesis is that PM exposure in this population will result in changes in vascular and endothelial response as assessed by flow-mediated dilatation of the brachial artery and various heart rate variability and blood endpoints. This study and similar studies of susceptible populations are needed to provide the EPA with information regarding the health risks associated with ambient levels of UF PM.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Other: Ultrafine Air Pollution Particulate Matter Other: Filtered Air Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Physiological Changes in Adults With Metabolic Syndrome Exposed to Concentrated Ultrafine Chapel Hill Air Particles
Study Start Date : December 2004
Actual Primary Completion Date : June 2011
Actual Study Completion Date : October 2013

Arm Intervention/treatment
Active Comparator: Ultrafine Air Pollution Particulate Matter
<2.5 microns concentrated from outside ambient air
Other: Ultrafine Air Pollution Particulate Matter
Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
Other Names:
  • ultrafine particulate matter
  • concentrated ambient particulates (CAPS)
Sham Comparator: Filtered Air
Filtered Air
Other: Filtered Air
Filtered Air
Other Name: clean air

Primary Outcome Measures :
  1. Changes in Vascular Function [ Time Frame: change from baseline 0 hr after exposure, and change from baseline 20 hr after exposure. There will be at leat 2 weeks between the exposures ]
    1. Measurement of dilatation of the brachial artery (flow mediated and nitroglycerin mediated)
    2. Measurement of vasoconstrictor/vasodialtor, pro-coagulant, or pro-inflammatory mediators into systemic circulation (by ELISA of plasma)
    3. Measurement of changes in plasma levels of circulating microparticles and endothelial progenitor cells (as indicators of vascular injury or remodeling)

Secondary Outcome Measures :
  1. Changes in heart rate variability [ Time Frame: change from baseline 0 hr after exposure, and change from baseline 20 hr after exposure. There will be at leat 2 weeks between the exposures ]
    10 minute electrocardiogram recording (measure by Holter ECG) in which the subject has been resting for 20 minutes prior. Collected on a Mortara H12+ 12-Lead ECG Recorder (Mortara Instrument, Inc., Milwaukee, WI). The digitally recorded ECGs were sampled at 180 Hz and all data were stored on flash cards before processing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 25-70 years old
  • Metabolic syndrome as defined by the participant having at least three of the following criteria:

    • Abdominal obesity: Men waist circumference >102 cm (>40 in) Women waist circumference >88 cm (>35 in)
    • Triglycerides: ≥150 mg/dL
    • HDL cholesterol: Men <40 mg/dL and Women <50 mg/dL
    • Blood pressure: ≥130/≥85 mmHg OR have a history of high blood pressure requiring medication
    • Fasting glucose: ≥100 mg/dL and ≤126 mg/dL
  • Normal resting electrocardiograph (ECG).

Exclusion Criteria:

  • Current smoker or smoking history within 3 months of study (defined as more than one pack of cigarettes in the past 3 months).
  • Oxygen saturation below 95% at the time of physical exam.
  • Blood pressure ≥160/≥100 mmHg
  • Fasting blood glucose >126 mg/dl
  • Hypersensitivity to nitroglycerin or other nitrates
  • Any chronic medical condition including active pulmonary disease, cardiovascular disease (coronary artery disease, heart failure, rhythm disturbances, etc.), neurological disease, liver disease, kidney disease, muscular disease, diabetes, other endocrine disease, hematologic/lymphatic disease, immune deficiency or autoimmune disease.
  • Medications specifically prohibited include nitrates or other vasodilators (exception here includes erectile dysfunction medications if the participant agrees to refrain for 96 hours prior to study), anti-arrhythmics, physician prescribed anti-inflammatory agents, physician prescribed antioxidants, insulin and other medications for the treatment of diabetes. Participants must refrain from all over-the-counter anti-inflammatory agents, including aspirin, ibuprofen, and naproxen, and anti-oxidants for a period of one week prior to exposure. Low dose aspirin and statin regimens are acceptable. Medications not specifically mentioned here may be reviewed by the investigators prior to a participant's inclusion in the study. Additionally, medication regimens must remain constant during the study.
  • Hepatitis B carriers
  • Skin diseases or sensitivity precluding the use of ECG electrodes
  • Active cancer, history of cancer within the last 5 years, untreated cancer. Potential participants may have a history of mild, treated skin cancer provided the condition does not interfere with ECG electrode placement.
  • No exposure will be conducted within 4 weeks of a respiratory tract infection.
  • History of serve migraines
  • Pregnant women or nursing mothers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01475968

United States, North Carolina
EPA Human Studies Facility
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
David Diaz-Sanchez
Environmental Protection Agency (EPA)
Principal Investigator: Robert B Devlin, PhD US EPA
Principal Investigator: Candice B Smith, PhD US EPA

Responsible Party: David Diaz-Sanchez, Biologist, Environmental Protection Agency (EPA) Identifier: NCT01475968     History of Changes
Other Study ID Numbers: XCON
04-1677 ( Other Identifier: UNC IRB )
First Posted: November 22, 2011    Key Record Dates
Last Update Posted: November 7, 2013
Last Verified: November 2013

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases